Floatz logo

CD47/SIRPA-BLOCKING AGENT ALX148

Hormone Receptor-Positive Breast Cancer

QuantumLeap Healthcare Collaborativeprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

111 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
Exemestane
Fujian Cancer Hospital
Phase 4BBB
Anastrozole
University of Illinois at Chicago
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Ribociclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

CD47/SIRPA-BLOCKING AGENT ALX148 is also rated in:

breast cancerActive
B
Indicative · Phase 2
60 / 100
View asset →
plasma cell myelomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
composite lymphomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →